Amarin AMRN
Amarin: quarterly report for the quarter ended Jun 30, 2022
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-22-014008
- Document
- 10-Q
- Exhibit 10.2
- Material contract
- Exhibit 10.3
- Material contract
- Exhibit 10.4
- Material contract
- Exhibit 10.5
- Material contract
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
- Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
- Usana Health Sciences USNA public float $328M, Jun 27, 2025
- Emergent BioSolutions EBS public float $343M, Jun 30, 2025
- Altimmune ALT public float $327M, Jun 30, 2025
